A Minimally Invasive Trial for Atrial Fibrillation Patients

The purpose of the CONVERGE clinical trial is to establish a safe, effective and minimally invasive surgery for atrial fibrillation (AFib).

If you have been diagnosed with atrial fibrillation, you may qualify for the Convergent Procedure, a "hybrid" approach that combines two AFib treatments into one therapy.

During this clinical trial, your medical care will be provided by board-certified doctors and hospitals that specialize in AFib research. You may also receive compensation for participating in this clinical trial.

Start Patient Screener 60-second survey
screener

The Convergent Procedure combines two therapies for atrial fibrillation into a single procedure that is typically performed in an electrophysiology lab.

Which Patients May Qualify?

You may be eligible for this AFib study if:

  • 18-80 You are between 18 and 80 years of age
  • wave-bg You experience persistent Atrial Fibrillation
  • wave-bg Your heart medications are not working
Next Step to Qualify
patient-bg

CONVERGE is a clinical trial that is now enrolling patients that experience persistent AFib with symptoms including fatigue, shortness of breath and chest pain.

Find Out If You Are Eligible

  • Call (844) 202-8199

    Monday - Friday, 8am - 8pm

    Call Now
  • OR
  • Take the Online Screener

    60-second survey

    Start Here